Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded at BNP Paribas Exane

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by investment analysts at BNP Paribas Exane to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, May 6th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Sanford C. Bernstein initiated coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, July 16th. They set a “market perform” rating for the company. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Finally, Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Six analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $23.95.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE FMS opened at $24.89 on Tuesday. The stock has a market cap of $13.37 billion, a P/E ratio of 13.10, a P/E/G ratio of 4.40 and a beta of 0.78. The firm’s 50-day simple moving average is $23.17 and its 200 day simple moving average is $22.91. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The company has a quick ratio of 0.86, a current ratio of 1.20 and a debt-to-equity ratio of 0.40.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%. The firm had revenue of $5.34 billion during the quarter. Equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.22 EPS for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of hedge funds have recently bought and sold shares of FMS. Moran Wealth Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after buying an additional 83,311 shares during the period. Pzena Investment Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% during the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after acquiring an additional 299,986 shares during the period. Ritholtz Wealth Management raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 252.7% during the first quarter. Ritholtz Wealth Management now owns 84,658 shares of the company’s stock valued at $1,910,000 after acquiring an additional 60,652 shares during the period. ABC Arbitrage SA lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after acquiring an additional 229,589 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 190.7% in the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock valued at $2,985,000 after acquiring an additional 86,798 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.